Vālenz Health Taps Vince Cole as CEO to Scale Self-Funded Plan Solutions

RADNOR, Pa. – June 01, 2026 – Vālenz Health®, a key player in simplifying self-funded healthcare plans, has appointed veteran executive Vince Cole as its new Chief Executive Officer. The move signals a strategic push to accelerate growth and expand the company's footprint in a market increasingly dominated by employers seeking control over rising medical costs.

Cole takes the helm from Rob Gelb, who, after a transformative seven-and-a-half-year tenure, will transition to the role of Non-Executive Chairman of the Board. The appointment is the culmination of a planned succession process designed to guide Vālenz into its next chapter of expansion, backed by its private equity sponsor, Kelso & Company.

"I am honored to join Valenz at such a pivotal moment," Cole stated in the official announcement. "The company has built a strong foundation, and I look forward to working with the team to expand impact, strengthen partnerships, and continue delivering on its mission to support strong, vigorous, and healthy lives for all."

A New Era of Growth Under a Seasoned Scaler

Vince Cole brings over three decades of leadership experience that spans the intricate intersections of healthcare services, insurance, and technology-driven business transformation. His background appears tailor-made for the challenges Vālenz aims to solve. Most recently, he served as CEO of Ontellus, the nation's largest technology-enabled medical and legal records retrieval business. This experience in a high-volume, tech-driven healthcare services environment is directly relevant to the data-intensive world of health plan administration.

Prior to Ontellus, Cole held CEO roles for the Americas at professional services firm Charles Taylor and at the publicly traded Crawford & Company, the world's largest provider of claims management solutions. His deep expertise in the claims management and insurance industries provides him with a unique perspective on the payment integrity and cost-containment pillars of the Vālenz platform. His earlier career includes executive positions at Genworth Financial and General Electric, rounding out a resume marked by leadership in complex, large-scale enterprises.

The strategic nature of this appointment was underscored by Vālenz's private equity sponsor. "Valenz is entering an exciting new phase of growth from a position of strength and confidence in the vision," said Hank Mannix, Investment Partner at Kelso & Company. "Vince brings deep experience operating at scale, a proven ability to drive organic growth, and a strong track record of building high-performance teams in dynamic and complex industries."

Building on a Foundation of Transformation

Cole inherits a company that has undergone a significant evolution. Outgoing CEO Rob Gelb is credited with orchestrating the company's successful transformation, marked by substantial organic growth and the acquisition and integration of eight separate businesses. Under his leadership, Vālenz Health was formally launched as a unified brand in 2019, consolidating four distinct companies to create a more integrated market offering.

This period was characterized by rapid expansion of capabilities. In 2020, the company introduced its enterprise data analytics platform, vLens, and a reference-based pricing model, Valenz Market-Sensitive (VMS®). The following years saw a string of strategic acquisitions, including Kozani Health for bill review in 2021, and a flurry of four integrations in 2022 that added stop-loss solutions, population health management, and provider credentialing to its portfolio.

More recently, the 2024 acquisition of Healthcare Bluebook, a leading cost and quality navigation platform, further bolstered the company's commitment to transparency for health plan members. This foundation of aggressive growth and integration culminated in the 2025 launch of ValenzONE, a next-generation solution featuring a variable co-pay model designed to incentivize members to choose more cost-effective care. Gelb's tenure established Vālenz as a formidable integrated platform, boasting a 99% client retention rate and a clear trajectory that attracted a new equity investment from Kelso in 2023.

Capitalizing on the Self-Funded Healthcare Boom

The leadership change at Vālenz Health comes at a critical moment for the U.S. healthcare industry. Self-funded health plans, where employers assume the financial risk for their employees' health claims, have become the dominant model for managing benefits. In 2023, these plans covered 65% of all workers, including 94% of employees at large firms. This shift is driven by a relentless rise in healthcare costs and a desire from employers for greater financial control, flexibility, and transparency than traditional, fully insured plans can offer.

The self-funded market is projected to grow from $20 billion in 2026 to $35 billion by 2033, creating a massive opportunity for companies that can effectively help employers manage their risk and control spending. Employers are no longer satisfied with opaque systems and are demanding data-driven insights, tools for member engagement, and integrated solutions that tackle costs across the entire healthcare journey—from pharmacy benefits to complex surgical procedures.

Vālenz Health has positioned its platform as a direct response to these market demands. By combining data analytics, care navigation, payment integrity, and provider network management into a single system, the company aims to provide the end-to-end visibility and control that self-funded employers crave. The appointment of a CEO with Cole's background in scaling technology and service operations suggests Vālenz is preparing to compete for a larger share of this expanding market, moving beyond its established base to challenge larger, more traditional third-party administrators (TPAs).

The Private Equity Playbook in Action

This executive transition exemplifies a classic private equity strategy. Kelso & Company, which made a significant new equity investment in Vālenz in 2023, is now deploying a seasoned operator to unlock the next stage of value. The initial phase under Rob Gelb focused on consolidation and building a comprehensive platform through acquisitions. The next phase under Vince Cole will likely focus on scaling that platform, optimizing operations for efficiency, and driving aggressive organic growth.

This playbook involves leveraging Cole's experience to refine the integrated model, expand market penetration, and enhance profitability. His mandate is not just to manage the company but to actively transform it into a larger, more dominant force in the healthcare benefits landscape. The move from a foundational, acquisitive CEO to a growth-oriented, operational CEO is a well-trodden path for PE-backed companies aiming for a high-value exit within their investment horizon. Cole's leadership is the catalyst Kelso is counting on to fully capitalize on the market trends and the robust platform built over the last several years.